NCT03169790 2025-02-24QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLImmunityBio, Inc.Phase 1/2 Withdrawn
NCT03167164 2025-02-21QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyImmunityBio, Inc.Phase 1/2 Withdrawn
NCT03167177 2025-02-21QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyImmunityBio, Inc.Phase 1/2 Withdrawn
NCT03197571 2025-02-21QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyImmunityBio, Inc.Phase 1/2 Withdrawn
NCT03574649 2025-02-21QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerImmunityBio, Inc.Phase 2 Withdrawn
NCT01933061 2014-02-04Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic MelanomaCelgenePhase 2 Withdrawn